Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer

NCT ID: NCT03731130

Last Updated: 2018-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-05

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational study to evaluate longitudinal quality of life according to standardized EORTC questionaires as well as functional Outcome, oncological outcome and toxicity in patients treated with neoadjuvant short term radiation or long-term chemoradiation followed by surgery

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Observational study to evaluate longitudinal quality of life in patients treated with neoadjuvant short-course Irradiation or neoadjuvant Long-Course chemoradiation followed by surgery. QoL will be evaluated by standardized EORTC questionaires QLQ C30 and CR29. Acute and late toxicity will be assessed according to CTCAE 4.03. Oncological Outcome will be assessed with regard to local and distant Control, Patterns of recurrence, freedom from Treatment failure and Overall survival. Correlations of physicians- and Patient-assessed functional outcomes are planned.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Cancer Quality of Life Radiation Therapy Chemoradiation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

neoadjuvant short term radiation

Treatment with neoadjuvant short term radiation therapy (5x5 Gy) followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire.

EORTC QLQ C30

Intervention Type OTHER

standardized questionaire

EORTC QLQ CR29

Intervention Type OTHER

standardized questionaire

neoadjuvant long-term chemoradiation

Treatment with neoadjuvant Long-term chemoradiation followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire

EORTC QLQ C30

Intervention Type OTHER

standardized questionaire

EORTC QLQ CR29

Intervention Type OTHER

standardized questionaire

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EORTC QLQ C30

standardized questionaire

Intervention Type OTHER

EORTC QLQ CR29

standardized questionaire

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histologically proven rectal Cancer without distant metastases
* indication for neoadjuvant Radiation or chemoradiation therapy according to multidiciplinary Evaluation
* age \>=18 years
* written informed consent
* ability to answer the standardized questionaires according to the treating physician

Exclusion Criteria

* age \< 18 years
* prior systemic therapy with regard to rectal Cancer
* distant metastasis
* second malignancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ludwig-Maximilians - University of Munich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Falk Roeder

Consultant

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Falk Roeder, MD

Role: PRINCIPAL_INVESTIGATOR

Ludwig-Maximilians Universität München

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Radiation Oncology, University Hospital, LMU Munich

Munich, Bavaria, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Falk Roeder, MD

Role: CONTACT

+49 89 4400 ext. 73729

Sabine Gerum, MD

Role: CONTACT

+49 89 4400 ext. 73770

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Falk Roeder, MD

Role: primary

+49 89 4400 73729

Sabine Gerum, MD

Role: backup

+49 89 4400 73729

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

V1 10.07.2018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Rectal Cancer CTC Trial
NCT07194616 RECRUITING NA